The company also anticipates opportunities for emergency use authorization in international markets before FDA approval. Tivic expects to leverage Entolimod for additional indications, including ...
Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...
CMND-100, a proprietary MEAI-based oral drug candidate, represents a potential breakthrough in AUD treatment, targeting the reduction of alcohol consumption and cravings through a novel mechanism of ...
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
Alnylam Pharmaceuticals' amyloidosis drug Amvuttra received Food and Drug Administration approval for an expanded indication.
Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upon FDA approval, commercial launch activities to commence immediately with ...
Information on the FDA review process for PMA applications can be found on the FDA website at: https://www.fda.gov/medical-devices/premarket-approval-pma/pma-review-process. There can be no assurance ...
Here's when St. Patrick's Day 2025 is, the origin of the holiday and what to know about the food dye that colors the holiday's trademark green beer.
(Nasdaq: NSPR), developer of the CGuardâ„¢ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth ...
including telehealth and drug companies that sell compounded versions of FDA-approved drugs. The Associated Press Health and Science Department receives support from the Howard Hughes Medical ...
The FDA is expected to decide on treatments for ... The Company is seeking approval for acute treatment of migraine with or without aura.